<DOC>
	<DOCNO>NCT01543568</DOCNO>
	<brief_summary>50 Patients recalcitrant exudative age-related macular degeneration history retinal subretinal fluid multiple intravitreal injection ranibizumab 0.5mg subsequently treat ranibizumab 2.0mg , incomplete responder 2.0mg ranibizumab .</brief_summary>
	<brief_title>Study Recalcitrant Age Related Macular Degeneration</brief_title>
	<detailed_description>The rationale TURF trial base great bind affinity VEGF Trap-eye , theoretically may prove effective recalcitrant wet AMD therefore may demonstrate positive impact visual acuity foveal anatomy subject history less optimal anatomical visual response multiple intravitreal injection 2.0mg ( super-dose ) ranibizumab . Based anatomical data VIEW1 VIEW2 trial , approximately 70 % VEGF-Trap eye patient evidence fluid OCT compare approximately 55 % ranibizumab patient . One potential interpretation clinical data increase bind affinity longer half-life VEGF-Trap eye result resolution fluid long duration effect . Patients enrol study history require monthly dose ranibizumab 2.0mg achieve maximum resolution fluid OCT increase visual acuity . These patient initially show minimal fluid resolution visual acuity gain treat Lucentis ( 0.5mg ranibizumab ) subsequently treat 2.0mg monthly . It expect treat patient 2.0mg EYLEA™ ( aflibercept injection eye ) maintain fluid resolution OCT visual acuity gain previously require super-dose ranibizumab .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Choroidal neovascularization secondary AMD History treatment 0.5mg ranibizumab follow 2.0mg ranibizumab AMD Best correct visual acuity study eye 20/20 20/400 use ETDRS chart Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Participation another simultaneous medical investigation trial Prior treatment antiVEGF therapy study eye within 28 day baseline Prior treatment PDT within past 3 month 4 prior PDT treatment . Presence significant subfoveal fibrosis atrophy . Prior treatment intravitreal aflibercept injection Prior treatment triamcinolone study eye within 6 month BSL . Prior treatment dexamethasone study eye within 30 day prior BSL Intraocular surgery ( include cataract surgery ) study eye within 2 month precede Baseline History vitrectomy surgery , submacular surgery , surgical intervention AMD study eye Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Uncontrolled glaucoma study eye ( defined IOP ≥ 30 mmHg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . History allergy fluorescein , ICG iodine , amenable treatment History retinal pigment epithelial tear rip</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Age relate Macular Degeneration</keyword>
	<keyword>Recalcitrant Age Related Macular Degeneration</keyword>
</DOC>